CoLucid pockets $4M for PhIII migraine drug trial

CoLucid Pharmaceuticals has injected some capital into its R&D tank with a $4 million funding tranche. The company has plans to drive toward a Phase III trial of lasmiditan, its lead drug for treating migraines, late next year, the Triangle Business Journal reports. The Durham, NC-based developer tapped Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures for the financing. Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.